I'm trying Aimovig and I’m hopeful.

If you have not yet heard of Aimovig, it’s a new preventative migraine treatment option for adults. After having many conversations about the medication with my neurologist, I’ve learned that it is a CGRP (Calcitonin gene-related peptide) inhibitor. From what I understand, the release of CGRP in the brain causes inflammation and this medication inhibits that inflammation and therefore may inhibit migraine.  

Given that this medication is unique and new to the market, I wanted to share my Aimovig experience - from a migraine patient’s perspective - so far

Why Try Cognitive Behavioral Therapy for Migraine?

Cognitive-behavioral therapy (CBT) is a psychological approach to managing headaches and migraine. The reason that people with headaches and migraine see a psychologist is not because those conditions are lacking a physical basis and it is all in their imaginations.

What Price for Migraine Relief?

I am going to assume that most of you taking the time to read this newsletter are aware of the four big Pharma companies competing to be the first to offer a drug that may lessen, or even prevent, migraines for the more than 36 million Americans affected by this debilitating neurological illness.

Current Neuromodulation Devices

With all of the anticipation of CGRP blockers, the sober news is that they will not be a savior for all migraine sufferers. First, like all pharmaceutical agents, they will not work for all migraine sufferers. Secondly, CGRP blockers are expensive (the current guess is that they will cost roughly $1000 a month). That is a big bill for insurance companies and therefore we do not know how difficult it will be to qualify for this therapy.

Novel Approaches to Migraine Treatment

The last few years has seen a groundswell of promising research and innovative medications and devices designed to prevent or abort a migraine episode. The Association of Migraine Disorders reports on what we believe to be credible research and treatments that will withstand rigorous testing. When AMD refers  to "novel approaches" we do not mean two minute YouTube guided imagery videos, ear piercings, or mentholated showers.  Yes, some people may have benefited from these approaches, but they need to be validated scientifically using rigorous methodology before receiving our endorsement.

Anti-CGRP Medications: An Update

A  breakthrough year indeed! With CGRP antibodies leading the charge.
 

2017: A breakthrough year for migraine?

The last year has been one of enormous promise for the prevention and treatment of migraine disease. Vigorous clinical trials of CGRP antibodies being aggressively pursued by Big Pharma, groundbreaking genetics research, and new developments in the area of neuromodulation have all led a renowned  migraine expert, Dr. David Dodick, Chair of the American Migraine Foundation, to declare "2017 will be a breakthrough year for migraine". Expectations are set very high indeed.

Advances in Non-Drug Therapies for Migraine

If you follow our Twitter postings with any degree of regularity you may recognize many of the devices/procedures summarized here. It was the recent release of the Cefaly II device that caused me to think that our followers deserved an up-to-date look at the devices available, especially if one was looking to add it to their treatment regimen.  Migraine treatment research has recently enjoyed a considerable, and hopeful, boost in both productivity and visibility. No doubt much of this is prompted by the potential market of 36 million enthusiastic consumers.

A Pharmaceutical Industry Update

This month, just prior to June Migraine Awareness Month, AMD is providing a comprehensive update on the FDA’s news and approvals of migraine medications. We think this is useful as it gives you a longitudinal look at the most current developments in migraine research including approvals, drugs in clinical trials, and recent industry news which could impact treatment options down the road.